The test’s ability to detect the SARS-CoV-2 virus is comparable to high-sensitivity PCR laboratory tests, but Lucira’s test fits right in the palm of your hand and comes with everything needed in one box, allowing New Zealanders to test anywhere at any time.įor every test, users have the option of generating a verified test record using LUCI Pass, an easy-to-use, web-based platform made available by Lucira Health.Īt present, Air New Zealand is completing a 3-month trial of Lucira Check-It tests at Auckland Airport with airline staff to gather data on local use of the test. The test is completely untethered, requiring no additional equipment typically required with conventional PCR testing.
The Lucira test uses nucleic acid amplification technology to deliver PCR-quality results in as little as 11 minutes for a positive result, 30 minutes for a negative result. Lucira’s test is the first molecular at-home test for COVID-19, as reported by the US FDA. (Nasdaq: LHDX) (“Lucira Health,” or “Lucira”), a medical technology company focused on the development and commercialisation of transformative and innovative infectious disease tests, today reported that the New Zealand Ministry of Health granted Lucira Health’s Check-It COVID-19 test a full exemption for use in New Zealand, heralding a new era in Test-to-Treat in the region. Lucira is a QB3 Startup in a Box and incubator alumni company.
0 kommentar(er)
